Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study.

Acta Oncol · 2024 · PMC11495122 · PMID 39415562

Europe PMC DOI

hedged sentences

0.6910

closest p · 13.8× alpha

0.6910

boldest claim

The sentences

did not reach statistical significancep = 0.691not close (p > 0.1)

36 months; p = 0.009), but did not reach statistical significance in stage IV OC (median: 39 months vs. 32 months; p = 0.691) [ 24 ].

also in 111,027 other papers

showed a trendno p-value reported

In our study, the use of NACT in patients with advanced disease showed a trend towards improved prognosis in the first 2 years, although longer-term effects were not as clearly detectable.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.